-
Je něco špatně v tomto záznamu ?
Prognostic factors in patients with uterine sarcoma: the SARCUT study
I. Zapardiel, M. Gracia Segovia, R. Macuks, R. Mancari, P. Achimas-Cadariu, G. Corrado, A. Bartusevicius, V. Sukhin, JC. Muruzabal, PJ. Coronado Martín, B. Gardella, JM. Piek, N. Concin, C. Arab, D. Papatheodorou, S. Polterauer, S. Iacoponi, T....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu multicentrická studie, časopisecké články
NLK
ProQuest Central
od 2018-01-01 do Před 6 měsíci
Health & Medicine (ProQuest)
od 2018-01-01 do Před 6 měsíci
PubMed
37192761
DOI
10.1136/ijgc-2022-004204
Knihovny.cz E-zdroje
- MeSH
- adenosarkom * terapie patologie MeSH
- endometriální stromální sarkom * terapie patologie MeSH
- leiomyosarkom * patologie MeSH
- lidé MeSH
- lokální recidiva nádoru MeSH
- nádory dělohy * patologie MeSH
- nádory endometria * patologie MeSH
- nádory pánve * MeSH
- prognóza MeSH
- retrospektivní studie MeSH
- sarkom * diagnóza MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
OBJECTIVE: Uterine sarcomas are a rare and heterogeneous group of malignancies that include different histological sub-types. The aim of this study was to identify and evaluate the impact of the different prognostic factors on overall survival and disease-free survival of patients with uterine sarcoma. METHODS: This international multicenter retrospective study included 683 patients diagnosed with uterine sarcoma at 46 different institutions between January 2001 and December 2007. RESULTS: The 5-year overall survival for leiomyosarcoma, endometrial stromal sarcoma, undifferentiated sarcoma, and adenosarcoma was 65.3%, 78.3%, 52.4%, and 89.5%, respectively, and the 5-year disease-free survival was 54.3%, 68.1%, 40.3%, and 85.3%, respectively. The 10-year overall survival for leiomyosarcoma, endometrial stromal sarcoma, undifferentiated sarcoma and adenosarcoma was 52.6%, 64.8%, 52.4%, and 79.5%, respectively, and the 10-year disease-free survival was 44.7%, 53.3%, 40.3%, and 77.5%, respectively. The most significant factor associated with overall survival in all types of sarcoma except for adenosarcoma was the presence of residual disease after primary treatment. In adenosarcoma, disease stage at diagnosis was the most important factor (hazard ratio 17.7; 95% CI 2.86 to 109.93). CONCLUSION: Incomplete cytoreduction, tumor persistence, advanced stage, extra-uterine and tumor margin involvement, and the presence of necrosis were relevant prognostic factors significantly affecting overall survival in uterine sarcoma. The presence of lymph vascular space involvement and administration of adjuvant chemotherapy were significantly associated with a higher risk of relapse.
Catalan Institute of Oncology L'Hospitalet de Llobregat Catalunya Spain
Department of Gynecology and Obstetrics Innsbruck Medical Univeristy Innsbruck Austria
Department of Obstetrics and Gynaecology Lithuanian University of Health Sciences Kaunas Lithuania
Gynecologic Oncology Department Clinica Diatros Barcelona Spain
Gynecologic Oncology Department Fondazione IRCCS Policlinico San Matteo Pavia Italy
Gynecologic Oncology Department Hospital Luis Tisné Universidad de Chile Santiago Chile
Gynecologic Oncology Department Hospital Universitario Miguel Servet Zaragoza Spain
Gynecologic Oncology Department Hospital Universitario Santa Cristina Madrid Spain
Gynecologic Oncology Department IRCCS Milan Italy
Gynecologic Oncology Department IRCCS Regina Elena National Cancer Institute Rome Italy
Gynecologic Oncology Department Metaxa Memorial Cancer Hospital Piraeus Greece
Gynecologic Oncology Department N N Alexandrov National Cancer Center Minsk Belarus
Gynecologic Oncology Department Tepecik Training and Research Hospital Clinics Konak Izmir Turkey
Gynecologic Oncology Department Torrecárdenas Hospital Complex Almeria Andalucía Spain
Gynecologic Oncology Unit Complejo Hospitalario de Navarra Pamplona Navarra Spain
Gynecologic Oncology Unit Hospital Clinico San Carlos Madrid Comunidad de Madrid Spain
Gynecologic Oncology Unit La Paz University Hospital Madrid Spain
Gynecological Oncology N N Alexandrov National Cancer Center Minsk Belarus
Obstetrics and Gynecology Clinica Universidad de Navarra Madrid Spain
Oncogynecology Grigoriev Institute for Medical Radiology NAMS of Ukraine Harkiv Ukraine
Oncology Radiology and Radiation Medicine 5 N Karazin Kharkiv National University Harkiv Ukraine
Riga East Clinical University Hospital Latvian Oncology Center Riga Latvia
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23011111
- 003
- CZ-PrNML
- 005
- 20230801132820.0
- 007
- ta
- 008
- 230718s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1136/ijgc-2022-004204 $2 doi
- 035 __
- $a (PubMed)37192761
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Zapardiel, Ignacio $u Gynecologic Oncology Unit, La Paz University Hospital, Madrid, Spain ignaciozapardiel@hotmail.com $1 https://orcid.org/0000000291757767
- 245 10
- $a Prognostic factors in patients with uterine sarcoma: the SARCUT study / $c I. Zapardiel, M. Gracia Segovia, R. Macuks, R. Mancari, P. Achimas-Cadariu, G. Corrado, A. Bartusevicius, V. Sukhin, JC. Muruzabal, PJ. Coronado Martín, B. Gardella, JM. Piek, N. Concin, C. Arab, D. Papatheodorou, S. Polterauer, S. Iacoponi, T. Nieto, MC. Lopez-Sanclemente, H. Trukhan, MM. Gil, I. Bakinovskaya, A. Dalamanava, M. Cucurull, D. Rovski, L. Baquedano, L. Chiva, M. Mardas, SA. Mavrichev, J. Klat, CA. Lopez de la Manzanara, Y. Yildirim, SARCUT Study Group
- 520 9_
- $a OBJECTIVE: Uterine sarcomas are a rare and heterogeneous group of malignancies that include different histological sub-types. The aim of this study was to identify and evaluate the impact of the different prognostic factors on overall survival and disease-free survival of patients with uterine sarcoma. METHODS: This international multicenter retrospective study included 683 patients diagnosed with uterine sarcoma at 46 different institutions between January 2001 and December 2007. RESULTS: The 5-year overall survival for leiomyosarcoma, endometrial stromal sarcoma, undifferentiated sarcoma, and adenosarcoma was 65.3%, 78.3%, 52.4%, and 89.5%, respectively, and the 5-year disease-free survival was 54.3%, 68.1%, 40.3%, and 85.3%, respectively. The 10-year overall survival for leiomyosarcoma, endometrial stromal sarcoma, undifferentiated sarcoma and adenosarcoma was 52.6%, 64.8%, 52.4%, and 79.5%, respectively, and the 10-year disease-free survival was 44.7%, 53.3%, 40.3%, and 77.5%, respectively. The most significant factor associated with overall survival in all types of sarcoma except for adenosarcoma was the presence of residual disease after primary treatment. In adenosarcoma, disease stage at diagnosis was the most important factor (hazard ratio 17.7; 95% CI 2.86 to 109.93). CONCLUSION: Incomplete cytoreduction, tumor persistence, advanced stage, extra-uterine and tumor margin involvement, and the presence of necrosis were relevant prognostic factors significantly affecting overall survival in uterine sarcoma. The presence of lymph vascular space involvement and administration of adjuvant chemotherapy were significantly associated with a higher risk of relapse.
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a leiomyosarkom $x patologie $7 D007890
- 650 12
- $a adenosarkom $x terapie $x patologie $7 D018195
- 650 _2
- $a prognóza $7 D011379
- 650 12
- $a endometriální stromální sarkom $x terapie $x patologie $7 D018203
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a lokální recidiva nádoru $7 D009364
- 650 12
- $a sarkom $x diagnóza $7 D012509
- 650 12
- $a nádory dělohy $x patologie $7 D014594
- 650 12
- $a nádory pánve $7 D010386
- 650 12
- $a nádory endometria $x patologie $7 D016889
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Gracia Segovia, Myriam $u Gynecologic Oncology Unit, La Paz University Hospital, Madrid, Spain $1 https://orcid.org/0000000287175270
- 700 1_
- $a Macuks, Ronalds $u Riga East Clinical University Hospital Latvian Oncology Center, Riga, Latvia
- 700 1_
- $a Mancari, Rosanna $u Gynecologic Oncology Department, IRCCS, Milan, Italy $u Gynecologic Oncology Department, IRCCS Regina Elena National Cancer Institute, Rome, Italy
- 700 1_
- $a Achimas-Cadariu, Patriciu $u Gynecologic Oncology Department, The Oncology Institute 'Prof Dr Ion Chiricuta' Cluj-Napoca, Cluj-Napoca, Romania
- 700 1_
- $a Corrado, Giacomo $u Policlinico Universitario Agostino Gemelli Dipartimento Scienze della Salute della Donna e del Bambino, Roma, Italy
- 700 1_
- $a Bartusevicius, Arnoldas $u Department of Obstetrics and Gynaecology, Lithuanian University of Health Sciences, Kaunas, Lithuania
- 700 1_
- $a Sukhin, Vladyslav $u Oncology, Radiology and Radiation Medicine, V N Karazin Kharkiv National University, Harkiv, Ukraine $u Oncogynecology, Grigoriev Institute for Medical Radiology NAMS of Ukraine, Harkiv, Ukraine $1 https://orcid.org/0000000244033707
- 700 1_
- $a Muruzabal, Juan C $u Gynecologic Oncology Unit, Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain
- 700 1_
- $a Coronado Martín, Pluvio J $u Gynecologic Oncology Unit, Hospital Clinico San Carlos, Madrid, Comunidad de Madrid, Spain
- 700 1_
- $a Gardella, Barbara $u Gynecologic Oncology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
- 700 1_
- $a Piek, Jurgen M $u Gynecologic Oncology Department, Catharina Hospital and Catharina Cancer Institute, Eindhoven, Netherlands
- 700 1_
- $a Concin, Nicole $u Department of Gynecology and Obstetrics, Innsbruck Medical Univeristy, Innsbruck, Austria $u Division of General Gynecology and Gynecologic Oncology, Department of Obstetrics and Gynecology, Gynecologic Cancer Unit, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $1 https://orcid.org/0000000297952643
- 700 1_
- $a Arab, Clemente $u Gynecologic Oncology Department, Hospital Luis Tisné. Universidad de Chile, Santiago, Chile
- 700 1_
- $a Papatheodorou, Dimitrios $u Gynecologic Oncology Department, Metaxa Memorial Cancer Hospital, Piraeus, Greece
- 700 1_
- $a Polterauer, Stephan $u Karl Landsteiner Institute for General Gynecology and Experimental Gynecologic Oncology, Vienna, Austria
- 700 1_
- $a Iacoponi, Sara $u Gynecologic Oncology Unit, La Paz University Hospital, Madrid, Spain
- 700 1_
- $a Nieto, Teresa $u Gynecologic Oncology Department, Hospital Universitario Santa Cristina, Madrid, Spain
- 700 1_
- $a Lopez-Sanclemente, Martha C $u Gynecologic Oncology Department, Torrecárdenas Hospital Complex, Almeria, Andalucía, Spain $u Gynecologic Oncology Department, Clinica Diatros, Barcelona, Spain
- 700 1_
- $a Trukhan, Hanna $u Gynecologic Oncology Department, N N Alexandrov National Cancer Center, Minsk, Belarus
- 700 1_
- $a Gil, Maria M $u Gynecologic Oncology Unit, La Paz University Hospital, Madrid, Spain
- 700 1_
- $a Bakinovskaya, Irina $u Gynecologic Oncology Department, N N Alexandrov National Cancer Center, Minsk, Belarus
- 700 1_
- $a Dalamanava, Alena $u Gynecologic Oncology Department, N N Alexandrov National Cancer Center, Minsk, Belarus
- 700 1_
- $a Cucurull, Marc $u Catalan Institute of Oncology, L'Hospitalet de Llobregat, Catalunya, Spain
- 700 1_
- $a Rovski, Dzmitry $u Gynecologic Oncology Department, N N Alexandrov National Cancer Center, Minsk, Belarus
- 700 1_
- $a Baquedano, Laura $u Gynecologic Oncology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain
- 700 1_
- $a Chiva, Luis $u Obstetrics and Gynecology, Clinica Universidad de Navarra, Madrid, Spain $1 https://orcid.org/0000000219083251
- 700 1_
- $a Mardas, Marcin $u Department of Gynecological Oncology, Poznan University of Medical Sciences, Poznan, Wielkopolskie, Poland
- 700 1_
- $a Mavrichev, Siarhei Anatolievich $u Gynecological Oncology, N N Alexandrov National Cancer Center, Minsk, Belarus
- 700 1_
- $a Klat, Jaroslav $u Obstetrics and Gynecology Department, University Hospital Ostrava, Ostrava, Moravskoslezský, Czech Republic
- 700 1_
- $a Lopez de la Manzanara, Carlos A $u Gynecologic Oncology Department, Hospital General Universitario de Ciudad Real, Ciudad Real, Castilla-La Mancha, Spain
- 700 1_
- $a Yildirim, Yusuf $u Gynecologic Oncology Department, Tepecik Training and Research Hospital Clinics, Konak, Izmir, Turkey
- 710 2_
- $a SARCUT Study Group
- 773 0_
- $w MED00009896 $t International journal of gynecological cancer : official journal of the International Gynecological Cancer Society $x 1525-1438 $g Roč. 33, č. 6 (2023), s. 897-904
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37192761 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230718 $b ABA008
- 991 __
- $a 20230801132816 $b ABA008
- 999 __
- $a ok $b bmc $g 1963485 $s 1197376
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 33 $c 6 $d 897-904 $e 20230605 $i 1525-1438 $m International journal of gynecological cancer $n Int J Gynecol Cancer $x MED00009896
- LZP __
- $a Pubmed-20230718
